References
- Callen JP. Myositis and malignancy. Curr Opin Rheumatol 1994; 6: 590–4.
- Lakhanpal S, Bunch TW, Ilstrup DM, Melton JL. Polymyositis-dermatomyositis and malignant lesions. Does an association exist? Mayo Clin Proc 1986; 61: 645–53.
- Sigurgeirsson B, Lindeloff B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population based study. N Engl J Med 1992; 326: 363–7.
- Maoz CR, Langevitz P, Livneh A, et al. High incidence of malignancies in dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 1998; 27: 319–24.
- Barnes BE. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 1976; 84: 68–76.
- Polyzos A, Tsavaris N, Giannopoulos A, et al. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. Cancer Chemother Pharmacol 1996; 38: 292–7.
- Polyzos A, Tsavaris N, Kosmas C, et al. Double bio-chemical modulation of 5-fluorouracil by methotrexate and folinic acid for the treatment of advanced colorectal cancer. Clin Drug Invest 1999; 17: 83–8.
- Marie I, Hatron PY, Lavesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999; 78 (3): 139–47.
- Nyui S, Osanai H, Ohba S, Masuoka H, Yoshida Y. Relapse of colon cancer followed by polymyositis: report of a case and review of the literature. Surg Today 1997; 27 (6): 559–62.
- Stone OJ. Dermatomyositis/polymyositis associated with internal malignancy: a consequence of how neoplasms alter generalized extracellular matrix in the host. Med Hypotheses 1993; 41: 48–51.